AMG-329 is under clinical development by Amgen and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient ...
Iolyx Therapeutics engaged in research and development focused on autoimmunity and ophthalmology to offer novel treatments for ocular diseases. The company is headquartered in Menlo Park, California, ...
Sicca features are the central clinical manifestations of Sjögren’s syndrome (SS), but recent studies have confirmed that primary SS has a systemic expression, including extraglandular manifestations.
Trusted, comprehensive information and support for living well with IBS.
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback